Global Pharma Deal Activity Gains Momentum as AI, Oncology and Advanced Therapies Drive August Growth
The global pharmaceutical and biotechnology industry continued to see strong dealmaking activity in August 2026, with companies pursuing acquisitions, licensing agreements, research collaborations, strategic partnerships and financing initiatives to strengthen pipelines, expand technology capabilities and accelerate the development of innovative therapies.
August deal activity highlighted several major industry priorities, including artificial intelligence-enabled drug discovery, oncology and precision medicine, advanced cell and gene therapies, biologics manufacturing, biosimilars and targeted delivery technologies. At the same time, strategic acquisitions and investments continued to help companies build differentiated platforms and expand their global capabilities.
Strategic Acquisitions Strengthen Pharma and Biotech Pipelines
Acquisitions remained an important growth strategy in August as pharmaceutical companies sought to add late-stage assets, strengthen therapeutic portfolios and expand specialized capabilities.
Jazz Pharmaceuticals announced an agreement to acquire Actio Biosciences for $820 million upfront and up to $500 million in contingent consideration, bringing Actio's lead asset ABS-1230 into Jazz's rare epilepsy portfolio. ABS-1230 is a first-in-class small molecule precision therapy targeting the KCNT1 ion channel for KCNT1-positive epilepsy, a rare genetic developmental and epileptic encephalopathy. The transaction strengthens Jazz's position in rare and severe epilepsies while adding a potentially differentiated clinical-stage asset.
Ipsen also completed its acquisition of Kartos Therapeutics, adding navtemadlin, a late-stage MDM2 inhibitor in Phase III development for myelofibrosis. The acquisition strengthens Ipsen's oncology portfolio and expands its presence in hematologic malignancies through a clinical-stage program.
In cell therapy, IASO Biotechnology completed its acquisition of Singapore-based MediSix Therapeutics. The transaction adds MediSix's T-cell engineering platform, R&D pipeline and international talent to IASO Bio's existing cell therapy capabilities, supporting its globalization strategy and strengthening its development, manufacturing and commercialization infrastructure.
AI and Data-Driven Drug Discovery Gain Strategic Importance
Artificial intelligence continued to move deeper into pharmaceutical R&D, with companies combining AI, machine learning, data science and advanced modeling platforms to improve drug discovery and clinical development.
Novo Nordisk and Amazon Web Services announced a strategic partnership focused on agentic AI and cloud technologies to accelerate drug discovery and modernize operations. The companies have established a co-innovation hub in London where scientists and engineers are combining AWS AI technologies with Novo Nordisk's scientific data and insights to shorten the path from drug target to first human dose.
Evotec and Odyssey Therapeutics also entered a strategic R&D collaboration focused on autoimmune and inflammatory diseases. Odyssey will leverage Evotec's data-driven discovery platform, screening capabilities and AI-enabled data science technologies to identify and validate small-molecule drug candidates across multiple disease targets.
HiRO and Differentia Biotech meanwhile signed an MOU to develop data-driven clinical trial solutions. Their collaboration will combine HiRO's global clinical operations, data science and real-world data expertise with Differentia's AI-powered digital twin and modeling and simulation platforms. The companies aim to develop simulation-informed approaches for trial design, patient selection and earlier development decision-making.
Oncology and Precision Medicine Remain Key Deal Drivers
Cancer research and precision medicine continued to attract partnerships aimed at improving patient selection, diagnostics and next-generation treatment development.
SOPHiA GENETICS entered a global collaboration with AstraZeneca to develop and validate two companion diagnostic programs supporting precision oncology therapies. The collaboration will advance decentralized diagnostic capabilities for solid tumors and hematological cancers, supporting efforts to connect patients with appropriate targeted treatments.
Genprex also partnered with Roche Diagnostics to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer. The collaboration will investigate TROP2 and PTEN-related biomarkers to refine identification of patients who may benefit from targeted treatment approaches.
Bristol Myers Squibb and Atrium Therapeutics continued their RNA therapeutics collaboration, with Atrium receiving another $15 million milestone payment following the successful delivery of a lead compound targeting an undisclosed cardiovascular indication. The broader collaboration focuses on discovering, developing and commercializing RNA-based therapies for cardiovascular diseases.
Biologics, Biosimilars and CDMO Expansion Accelerate
Manufacturing and biologics capabilities remained another major area of strategic investment as companies sought greater control over complex production platforms and global supply.
Samsung Biologics announced a KRW 3 trillion rights offering to support its long-term growth strategy across capacity, portfolio and geographic expansion. Approximately KRW 2.71 trillion of the proceeds is planned for the acquisition of PolyPeptide Group, while around KRW 290 billion is earmarked for expansion of Bio Campus II. The transaction and investment program are designed to strengthen Samsung Biologics' position as a global CDMO.
Piramal Pharma completed the acquisition of an additional 40.67% stake in Hyderabad-based Yapan Bio for ₹76 crore ($7.95 million), taking its ownership to 74%. The transaction strengthens Piramal Pharma's biologics CDMO capabilities in vaccines and biologics and expands its integrated large-molecule service offering.
Shanghai Henlius Biotech and Sandoz also expanded their global biosimilars collaboration to cover up to 10 proposed monoclonal antibody and/or antibody-drug conjugate biosimilar products or components. Sandoz will receive exclusive rights outside China for registration and commercialization of the partnered products, while Henlius will support development, manufacturing and supply.
Xcellon Biologics further expanded its CRDMO capabilities by agreeing to acquire a GMP biologics manufacturing facility from NextCure. The transaction is designed to establish Xcellon as an end-to-end CRDMO with capabilities spanning discovery through clinical supply, particularly in bioconjugates and complex biologics.
Advanced Therapies and Targeted Delivery Attract New Investment
Innovative therapeutic platforms also drew strategic partnerships and financing during August.
CREATE Medicines entered a research collaboration with Monash University and the Monash Institute of Pharmaceutical Sciences to develop targeted lipid nanoparticle technologies for in vivo immune programming. The partners will work on targeted CAR therapy using LNP technology designed to improve cell-specific delivery of therapeutic payloads. CREATE will receive a worldwide exclusive license to intellectual property arising from the collaboration.
Mediar Therapeutics entered a collaboration and option agreement with Ono Pharmaceutical to develop novel treatments for fibro-inflammatory diseases. The partnership will leverage Mediar's fibrosis-focused discovery platform and myofibroblast expertise, with Ono receiving an exclusive option to license worldwide rights to develop and commercialize the programs.
Ratio Therapeutics meanwhile closed a $70 million Series C financing to advance its radiopharmaceutical pipeline. The funding will support its lead program in advanced sarcomas, move a next-generation radioligand therapy candidate into clinical development, expand oncology targets and strengthen manufacturing capabilities.
Global Partnerships Expand Clinical and Commercial Reach
Pharmaceutical and healthcare organizations also continued to form international alliances aimed at improving clinical research, commercialization and access to innovative technologies.
Monash Health and Data4Life signed an MoU to strengthen clinical research collaboration, with a focus on optimizing clinical trial timelines and patient enrollment, standardizing health data and supporting professional training in clinical research. The partnership forms part of Monash Health's broader effort to strengthen international health alliances.
Northwest Biotherapeutics and Saudi Pharmaceutical Industries and Medical Appliance Company (SPIMACO) also signed an MOU to explore collaboration around the approval, commercialization, supply and technology transfer of DCVax-L for glioblastoma in Saudi Arabia. The potential partnership could later expand to other indications and GCC markets.
Pharma Deal Outlook: Technology and Therapeutic Innovation Shape Growth
August 2026 deal activity demonstrates that pharmaceutical companies are increasingly using partnerships and acquisitions not only to expand pipelines but also to secure the technologies, manufacturing platforms and data capabilities needed for long-term growth.
AI-enabled drug discovery, oncology, precision medicine, biologics manufacturing, biosimilars, cell and gene therapies, radiopharmaceuticals and targeted delivery emerged as prominent areas of activity. The combination of strategic acquisitions with technology-focused collaborations also highlights a broader shift toward integrated innovation models.
As competition for differentiated therapies and advanced platforms intensifies, pharma and biotech companies are likely to continue using M&A, licensing, research partnerships and strategic investments to access emerging science, accelerate development timelines and expand global commercialization capabilities. August's transactions underscore how the convergence of biotechnology, AI, precision medicine and advanced manufacturing is shaping the next phase of growth across the global life sciences industry.